Prime Medicine
PRME
115 hedge funds and large institutions have $467M invested in Prime Medicine in 2024 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 39 increasing their positions, 35 reducing their positions, and 13 closing their positions.
77% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 13
11% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 35
10% more funds holding
Funds holding: 105 → 115 (+10)
8% more capital invested
Capital invested by funds: $433M → $467M (+$33.3M)
5.33% more ownership
Funds ownership: 50.25% → 55.58% (+5.3%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
17% less call options, than puts
Call options by funds: $407K | Put options by funds: $489K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Alphabet Inc
Mountain View,
California
|
+$24.3M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$23.4M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$21.7M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$15.1M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1.71M |
| 2 |
NAMA
Nikko Asset Management Americas
New York
|
-$1.17M |
| 3 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$1.17M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$1.06M |
| 5 |
Walleye Capital
New York
|
-$439K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GWS
126
Glassman Wealth Services
Vienna,
Virginia
| – | -$913 | -103 | Closed |
|
|
C
127
Covestor
London,
United Kingdom
| – | -$8 | -1 | -7% |
|
128
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | +$30 | +4 | +9% |
|
PRME Hedge Fund Activity: Q1 2024 in Review
115 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Prime Medicine (PRME) for Q1 2024, worth a combined $467M — up 7.7% from $433M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new PRME positions and 13 closed out — a net gain of 10 holders — while 39 added to existing stakes and 35 trimmed.
The largest buyer was Alphabet Inc, adding an estimated $24.3M. The largest seller was Morgan Stanley, cutting an estimated $1.71M.
- 115 institutional investors held Prime Medicine (PRME) as of Q1 2024, up from 105 in Q4 2023.
- Funds reported $467M of Prime Medicine stock for Q1 2024, up 7.7% quarter-over-quarter.
- 23 funds opened new Prime Medicine positions in Q1 2024 and 13 closed out, a net change of +10 holders.
- The largest Prime Medicine buyer in Q1 2024 was Alphabet Inc, an estimated $24.3M added.
- The largest Prime Medicine seller in Q1 2024 was Morgan Stanley, an estimated $1.71M sold.
Based on aggregated 13F filings for Q1 2024.